SDI Webinar: Wednesday, January 21st, 1:00 PM EST

At the conclusion of this session, attendees will have a basic understanding of:

  • The public health impact of congenital cytomegalovirus (cCMV) infection and its significance as a major cause of newborn morbidity in the United States.
  • cCMV screening’s clinical purpose, economic value, and position alongside established newborn screening tests.
  • Why saliva testing is preferred over dried blood spot methods for accurate cCMV screening.
  • Saliva-based PCR testing methodology and Implementation: How it works; proper collection techniques; sensitivity and specificity compared to other methods (urine, dried blood spot).
  • Clinical implications and management of infants who screen positive: Confirmatory testing, audiological and developmental monitoring, treatment, prognosis and outcome, and family counseling and support.

 

Highlights of the session include:

  • A live, interactive Q&A with the speakers
  • Eligibility to earn P.A.C.E.® Continuing Education credits
  • An opportunity to reconnect with peers and industry leaders focused on innovation in diagnostics

 

Attend the live webinar to participate in our Q&A session with our speakers. All presentations will be available to view on our webinar page after the event. Eligible participants can earn P.A.C.E.® credits.

About Our Speakers

Mark R. Schleiss, MD, is a Professor of Pediatrics at the University of Minnesota Medical School. He is a leading researcher in congenital cytomegalovirus (CMV) infection, a major public health problem causing substantial morbidity in newborns. His laboratory focuses on developing CMV vaccines and studying how maternal immune responses protect the fetus from infection. Dr. Schleiss’s translational research also examines the feasibility of implementing newborn screening programs for congenital CMV infection.

Jack Hysell is the Director of Solutions Engineering for Primary.Health. He connects Primary.Health technology with the real needs of public health labs, providers, and partners, designing solutions that meet customer requirements, strengthen the company’s platform, and set up teams for successful delivery.

 

Additional Information

Webinar attendees are eligible for 1 contact hour of continuing education (advanced level of instruction). SalivaDirect, Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program.

Please email [email protected] with questions or comments. Thank you, and we hope you’ll join us!